K-Ras and its inhibitors towards personalized cancer treatment: Pharmacological and structural perspectives

Area of Science:

• Oncology
• Pharmacogenomics
• Molecular Biology

Background:

• Personalized medicine, driven by genetic and genomic biomarkers, revolutionizes cancer treatment by predicting disease progression and therapy response.
• Pharmacogenomics is increasingly recognized for its role in developing safer, more effective drugs, as advocated by the U.S. Food and Drug Administration.
• Tumor-specific gene mutations, like B-Raf and K-Ras, significantly impact anticancer drug efficacy, with K-Ras mutations prevalent in pancreatic, colon, and lung cancers.

Purpose of the Study:

• To review the Ras/Raf/MEK/ERK signaling pathway, focusing on K-Ras mutations as a therapeutic target.
• To discuss inhibitors targeting K-Ras and their structure-activity relationships (SARs).
• To highlight the development of novel anticancer agents based on K-Ras as a biomarker and therapeutic target.

Main Methods:

• Literature review of studies on the Ras/Raf/MEK/ERK pathway.
• Analysis of K-Ras mutations in various carcinomas.
• Examination of farnesylation inhibitors and their clinical trial status.

Main Results:

• K-Ras mutations are identified as key clinical biomarkers and therapeutic targets in several major cancer types.
• Various Ras pathway inhibitors, including Tipifarnib and several peptidomimetics/bi-substrate inhibitors, are in clinical development.
• Structure-activity relationship (SAR) studies are crucial for designing effective K-Ras inhibitors.

Conclusions:

• Mutant K-Ras represents a significant target for precise cancer therapy.
• Ongoing research into K-Ras inhibitors holds promise for improved anticancer drug development.
• Understanding the Ras/Raf/MEK/ERK pathway is essential for advancing personalized oncology.